Wednesday, November 11, 2009

FDA approves Romidepsin for CTCL....

We knew that, Romidepsin (Istodax), is an anticancer antibiotic undergoing clinical trials as a treatment for cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and a variety of other cancers.

About Romidepsin :

Romidepsin, is a natural product obtained from the bacteria Chromobacterium violaceum, and works by blocking enzymes known as histone deacetylases and inducing apoptosis in tumor cells. It is sometimes referred to as depsipeptide, after the class of molecules to which it belongs.

FDA Approval ( Nov. 6, 2009) : The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL). Patients with localized CTCL on the skin are treated with topical agents or phototherapy, but chemotherapy may be used if the cancer advances. Istodax interferes with processes required for cell replication. It is intended to be used in patients when CTCL gets worse or comes back after at least one other type of chemotherapy has been used. Other drugs approved for CTCL are Zolinza (vorinostat), Ontak (denileukin difitox), and Targretin (bexarotene). More...

No comments: